Zydus Lifesciences Ltd (Zydus Lifesciences) is a life sciences company that focuses on the discovery, development, manufacturing, and marketing of healthcare therapies. The company's product portfolio includes finished dosage human formulations, active pharmaceutical ingredients (APIs), animal healthcare products, and consumer wellness products. Zydus Lifesciences serves diverse customer needs across the globe, supplying its products in the US, India, Europe, and emerging markets, including countries in Latin America, the Asia Pacific region, and Africa. The company operates through two operating segments: Pharmaceuticals and Consumer Products.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Zydus Lifesciences emphasizes innovative research and development (R&D) approaches to improve healthcare access. The company meets urgent needs through sustainable solutions, maintaining the availability of essential medicines at reasonable prices, thereby advancing health outcomes for underserved communities. Zydus Lifesciences’ R&D initiatives include developing liquid oral formulations for geriatric and pediatric patients with dysphagia, advancing first-to-market generics to sustain an affordable drug supply, and delivering India’s first oral treatment for anemia associated with chronic kidney disease (CKD). The company also works closely with strategic partners to broaden access to vaccines and biologic products across emerging and developed markets, strengthening the worldwide availability of essential healthcare interventions. The Zydus Lifesciences Research Center (ZRC) is the company’s dedicated research arm, supporting drug discovery and development from concept through IND-enabling preclinical and clinical studies. The Pharmaceutical Technology Center (PTC) focuses on developing pharmaceutical technologies and formulations. The Zydus Active Pharmaceutical Ingredients (API) Park focuses on the development and manufacture of active pharmaceutical ingredients. The Vaccine Technology Center (VTC) specializes in the development and production of diverse vaccine products. In FY2026, the company spent INR22,732 million on its R&D activities, which, as a percentage of revenue, stood at 8.3% and grew 22.5% YoY. As of March 2026, the company had 10 R&D centers dedicated to NCEs, APIs, generics, vaccines, biosimilars, and wellness products. As of March 2026, the company had 142 filed patents and 19 patents granted.